Effect of long-term haloperidol treatment on striatal neuropeptides: relation to stereotyped behavior.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 0045503 Publication Model: Print Cited Medium: Print ISSN: 0006-8993 (Print) Linking ISSN: 00068993 NLM ISO Abbreviation: Brain Res Subsets: MEDLINE
    • Publication Information:
      Original Publication: Amsterdam Elsevier/North-Holland Biomedical Press.
    • Subject Terms:
      Dopamine Antagonists/*pharmacology ; Haloperidol/*pharmacology ; Neostriatum/*chemistry ; Neuropeptides/*metabolism ; Stereotyped Behavior/*drug effects; Animals ; Behavior, Animal/drug effects ; Dopamine Agonists/pharmacology ; Dynorphins/metabolism ; Enkephalins/metabolism ; Male ; Neostriatum/drug effects ; Radioimmunoassay ; Rats ; Rats, Sprague-Dawley ; Receptors, Dopamine D1/agonists ; Receptors, Dopamine D2/agonists ; Sensitivity and Specificity ; Somatostatin/metabolism ; Substance P/metabolism ; Time Factors
    • Abstract:
      Behavioral and biochemical responses to D1 and D2 dopamine (DA) agonists were used to evaluate the participation of striatal peptidergic mechanisms in the motor function alterations that attend chronic neuroleptic treatment. Rats, given haloperidol (1 mg/kg, i.c.) for 21 consecutive days, were randomly allocated to one of the following treatments: the D1 agonist SKF 38393, the D2 agonist quinpirole, their combination or saline. Stereotyped behavior and neuropeptide levels were evaluated after 5 days treatment and 4 days washout. Haloperidol increased most oral behaviors including licking, chewing and biting as well as striatal enkephalin and somatostatin levels. Subsequent treatment with SKF 38393 diminished the haloperidol-induced increase in licking and chewing; quinpirole reduced chewing behavior. The administration of both agonists together decreased chewing and biting. Neither DA agonist alone, nor their combination, reduced the haloperidol-induced increase in enkephalin levels. Both SKF 38393 and quinpirole, when given alone, tended to decrease the haloperidol-induced increase in somatostatin levels; when both D1 and D2 agonists were administered together, somatostatin levels declined significantly. These results suggest that somatostatin- but not enkephalin-containing striatal neurons contribute to the expression of haloperidol-induced stereotypies.
    • Accession Number:
      0 (Dopamine Agonists)
      0 (Dopamine Antagonists)
      0 (Enkephalins)
      0 (Neuropeptides)
      0 (Receptors, Dopamine D1)
      0 (Receptors, Dopamine D2)
      33507-63-0 (Substance P)
      51110-01-1 (Somatostatin)
      74913-18-1 (Dynorphins)
      J6292F8L3D (Haloperidol)
    • Publication Date:
      Date Created: 19960826 Date Completed: 19970325 Latest Revision: 20190614
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/0006-8993(96)00461-1
    • Accession Number:
      8883854